Incyte Corp Q3 2024 10-Q Filing
Ticker: INCY · Form: 10-Q · Filed: Oct 29, 2024 · CIK: 879169
Sentiment: neutral
Topics: 10-Q, financials, revenue, biotech
TL;DR
Incyte's Q3 10-Q shows revenue from products, royalties, and milestones for 2024 vs 2023.
AI Summary
Incyte Corporation filed its 10-Q for the period ending September 30, 2024. The company reported revenue from product sales and royalties, with specific figures for the third quarter and year-to-date periods of 2024 compared to 2023. The filing details financial performance and operational segments, including milestone and contract revenues.
Why It Matters
This filing provides investors with the latest financial performance data for Incyte Corporation, crucial for understanding the company's revenue streams and operational health in the competitive biopharmaceutical market.
Risk Assessment
Risk Level: medium — As a biopharmaceutical company, Incyte faces inherent risks related to drug development, regulatory approvals, and market competition, which are reflected in its financial reporting.
Key Numbers
- 2024-09-30 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 2024-10-29 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- Incyte Corp (company) — Filer of the 10-Q
- 20240930 (date) — End of the reporting period
- 20241029 (date) — Filing date
FAQ
What were Incyte's product revenues for the third quarter of 2024?
The filing indicates product revenues for the period July 1, 2024, to September 30, 2024, but the specific dollar amount is not detailed in this header information.
How do the year-to-date product revenues for 2024 compare to 2023?
The filing provides data points for product revenues for the periods January 1, 2024, to September 30, 2024, and January 1, 2023, to September 30, 2023, allowing for comparison, though specific values are not in the header.
What is the reporting period for this 10-Q filing?
The conformed period of report is September 30, 2024.
When was this 10-Q filing submitted to the SEC?
The filing was submitted on October 29, 2024.
Does the filing include information on milestone and contract revenues?
Yes, the filing includes data points for 'MilestoneAndContractRevenuesMember' for the third quarter and year-to-date periods of 2024 and 2023.
Filing Stats: 4,597 words · 18 min read · ~15 pages · Grade level 19.6 · Accepted 2024-10-29 16:02:00
Filing Documents
- incy-20240930.htm (10-Q) — 1625KB
- exh101_formofusexecutiveof.htm (EX-10.1) — 67KB
- exh102_formofusrsuawardagr.htm (EX-10.2) — 44KB
- exh103_usformofexecutiveof.htm (EX-10.3) — 64KB
- exh104_usformofrsuawardagr.htm (EX-10.4) — 45KB
- incy-9302024xex311.htm (EX-31.1) — 10KB
- incy-9302024xex312.htm (EX-31.2) — 10KB
- incy-9302024xex321.htm (EX-32.1) — 4KB
- incy-9302024xex322.htm (EX-32.2) — 4KB
- 0000879169-24-000172.txt ( ) — 8619KB
- incy-20240930.xsd (EX-101.SCH) — 64KB
- incy-20240930_cal.xml (EX-101.CAL) — 73KB
- incy-20240930_def.xml (EX-101.DEF) — 370KB
- incy-20240930_lab.xml (EX-101.LAB) — 750KB
- incy-20240930_pre.xml (EX-101.PRE) — 578KB
- incy-20240930_htm.xml (XML) — 1036KB
: FINANCIAL INFORMATION
PART I: FINANCIAL INFORMATION 3 Item 1.
Financial Statements
Financial Statements 3 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Operations 4 Condensed Consolidated Statements of Comprehensive Income (Loss) 5 Condensed Consolidated Statements of Stockholders' Equity 6 Condensed Consolidated Statements of Cash Flows 8 Notes to Condensed Consolidated Financial Statements 9 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 28
Forward-Looking Statements
Forward-Looking Statements 28 Summary Risk Factors 31 Item 3.
Quantitative and Qualitative Disclosures about Market Risk
Quantitative and Qualitative Disclosures about Market Risk 57 Item 4.
Controls and Procedures
Controls and Procedures 57
: OTHER INFORMATION
PART II: OTHER INFORMATION Item 1A.
Risk Factors
Risk Factors 58 Item 5. Other Information 84 Item 6. Exhibits 86
Signatures
Signatures 87 2 Table of Contents
: FINANCIAL INFORMATION
PART I: FINANCIAL INFORMATION
Financial Statements
Item 1. Financial Statements INCYTE CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except number of shares and par value) September 30, 2024 December 31, 2023* (unaudited) ASSETS Current assets: Cash and cash equivalents $ 1,304,109 $ 3,213,376 Marketable securities—available-for-sale (amortized cost $ 463,921 and $ 442,816 as of September 30, 2024 and December 31, 2023, respectively; allowance for credit losses $ 0 as of September 30, 2024 and December 31, 2023) 467,235 442,667 Short term equity investments 3,344 — Accounts receivable 758,450 743,557 Inventory 70,442 62,972 Prepaid expenses and other current assets 205,128 182,830 Total current assets 2,808,708 4,645,402 Restricted cash 1,737 1,845 Long term equity investments 27,566 187,716 Inventory 297,974 206,965 Property and equipment, net 773,102 751,513 Finance lease right-of-use assets, net 25,072 25,535 Other intangible assets, net 119,994 123,545 Goodwill 155,593 155,593 Deferred income tax asset 762,310 631,886 Other assets, net 40,378 52,107 Total assets $ 5,012,434 $ 6,782,107 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 178,710 $ 109,601 Accrued compensation 150,722 153,348 Accrued and other current liabilities 1,127,951 935,569 Finance lease liabilities 3,932 3,439 Acquisition-related contingent consideration 40,335 38,422 Total current liabilities 1,501,650 1,240,379 Acquisition-related contingent consideration 166,665 173,578 Finance lease liabilities 28,223 29,162 Other liabilities 144,676 149,151 Total liabilities 1,841,214 1,592,270 Commitments and contingencies (Note 16) Stockholders' equity: Preferred stock, $ 0.001 par value; 5,000,000 shares authorized; none issued or outstanding — — Common stock, $ 0.001 par value; 400,000,000 shares authorized; 192,798,328 and 224,286,862 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 192 224 Additional paid-in ca